COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors

15/06/2017 - 22:30

Press Release Montrouge, France, June 15, 2017 DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) announced [...]

DBV Technologies Annonce les Résultats de son Assemblée Générale Mixte 2017

15/06/2017 - 22:30

Informations Réglementées Montrouge, France, le 15 juin 2017, 22h30 CEST DBV Technologies Annonce les Résultats de son Assemblée Générale Mixte 2017 Toutes les résolutions ont été adoptées L'Assemblée Générale Mixte de [...]

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

15/06/2017 - 22:30

AMF REGULATED INFORMATION Montrouge, France, June 15, 2017 DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting Shareholders approve all proposed resolutions DBV Technologies ( [...]

NANOBIOTIX a présenté de nouvelles données translationnelles lors du workshop d'Immunothérapie organisé par l'ASTRO, le NCI et le SITC

15/06/2017 - 21:43

NANOBIOTIX A PRESENTE DE NOUVELLES DONNEES TRANSLATIONNELLES LORS DU WORKSHOP D'IMMUNOTHERAPIE ORGANISE PAR L'ASTRO, LE NCI ET LE SITC Données translationelles montrant une activation du système immunitaire contre les [...]

NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop

15/06/2017 - 21:43

NANOBIOTIX: NEW TRANSLATIONAL DATA PRESENTED AT ASTRO, NCI AND SITC'S IMMUNOTHERAPY WORKSHOP Translational data showing tumor immune activity and positive Tumor Infiltrating Lymphocytes (TILs) in human and mouse model [...]

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

15/06/2017 - 20:00

FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine Sandoz looks [...]

Solon Eiendom ASA - Primary insider notification

15/06/2017 - 18:02

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 15 June 2017) Solon Eiendom ASA Board member Edvin Austbø (through his wholly owned company Alden AS) has [...]

Nestlé to explore strategic options for its US confectionery business

15/06/2017 - 18:02

This press release is also available in Français (pdf) and Deutsch (pdf) ....................................... Vevey, 15 June 2017 Nestlé to explore strategic options for its US confectionery business Nestlé will [...]

Solon Eiendom ASA - Primary insider notification

15/06/2017 - 17:59

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 15 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company [...]

Participation de Nicox à la Convention Internationale BIO 2017

15/06/2017 - 17:45

Participation de Nicox à la Convention Internationale BIO 2017 15 juin 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de Recherche et [...]

Nicox to present at the 2017 BIO International Convention

15/06/2017 - 17:45

Nicox to present at the 2017 BIO International Convention June 15, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Emmet [...]

ThromboGenics Long-time Non-executive Director Thomas Clay Appointed Chairman of the Board of Directors

15/06/2017 - 17:40

Leuven, Belgium, 15 June 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announces that the Board has appointed long-time non-executive [...]

Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of vested restricted stock units

15/06/2017 - 15:09

Lars Lund-Roland, member of the Board of Targovax ASA, has on 15 June 2017 subscribed for 16,394 shares in Targovax ASA at a price of NOK 0.10 per share in connection with settlement of vested restricted stock units (" [...]

RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection

15/06/2017 - 14:00

Subject to a successful outcome and any additional regulatory feedback, the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded [...]

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference

15/06/2017 - 13:00

Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 15 June 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug [...]

uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies

15/06/2017 - 13:00

-- Study published in Molecular Therapy provides proof of concept of successful cross-administration of AAV5- and AAV1-based gene therapies -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 15, 2017 (GLOBE [...]

NCSBN CEO Benton Receives Great Cross of Spanish Nursing from the Spanish General Council of Nursing

15/06/2017 - 12:00

CHICAGO, June 15, 2017 (GLOBE NEWSWIRE) -- NCSBN CEO David Benton, RGN, PhD, FFNF, FRCN, FAAN, received the Great Cross of Spanish Nursing in the Gold Category from the Spanish General Council of Nursing in Barcelona, [...]

Pöyry and Betulium sign co-operation agreement to unlock full value chain benefits for clients in bio-based businesses

15/06/2017 - 11:00

Pöyry and Betulium have signed a Letter of Intent (LOI) for co-operation that will enable both companies to serve their clients better in bio-based businesses. Pöyry and Betulium share common objectives in bioindustry: [...]

Zealand increases its share capital as a consequence of exercise of employee warrants

15/06/2017 - 10:11

Copenhagen, June 15, 2017 - Zealand Pharma ("Zealand") has increased its share capital by a nominal amount of DKK 8,537 divided into 8,537 new shares with a nominal value of DKK 1 each. The increase is a consequence of [...]